Kiadis Pharma’s primary objective is to become a leading biopharmaceutical company focused on developing and commercializing therapeutic products in cell-based immunotherapy. We aim to develop products that provide safer and more efficacious treatment options for cancer and blood disorder patients, improving their survival rate and quality of life.
Media and Investor Contact
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications
Tel: +44 (0) 203 709 5708
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015 under the symbol KDS.
Mar 31 2017Full Year Results 2016
Aug 25 2017Half Year Results 2017